A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile
…, C Kotash, P Zhao, S Megati, I Yurgelonis… - …, 2013 - microbiologyresearch.org
The Clostridium difficile toxins A and B are primarily responsible for symptoms of C. difficile
associated disease and are prime targets for vaccine development. We describe a plasmid-…
associated disease and are prime targets for vaccine development. We describe a plasmid-…
Nirmatrelvir, an orally active Mpro inhibitor, is a potent inhibitor of SARS-CoV-2 Variants of Concern
DK Rai, I Yurgelonis, P McMonagle, HA Rothan, L Hao… - BioRxiv, 2022 - biorxiv.org
New variants of SARS-CoV-2 with potential for enhanced transmission, replication, and
immune evasion capabilities continue to emerge causing reduced vaccine efficacy and/or …
immune evasion capabilities continue to emerge causing reduced vaccine efficacy and/or …
Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces …
…, JW Coleman, M Lee, C Kotash, I Yurgelonis… - Journal of …, 2008 - Am Soc Microbiol
Recombinant vesicular stomatitis virus (rVSV) has shown great potential as a new viral vector
for vaccination. However, the prototypic rVSV vector described previously was found to be …
for vaccination. However, the prototypic rVSV vector described previously was found to be …
[HTML][HTML] Generation of a VeroE6 Pgp gene knock out cell line and its use in SARS-CoV-2 antiviral study
Y Zhu, J Binder, I Yurgelonis, DK Rai, S Lazarro… - Antiviral research, 2022 - Elsevier
Vero cells are widely used for antiviral tests and virology research for SARS-CoV-2 as well
as viruses from various other families. However, Vero cells generally express high levels of …
as viruses from various other families. However, Vero cells generally express high levels of …
Horizontal transmission of cytomegalovirus in a rhesus model despite high-level, vaccine-elicited neutralizing antibody and T-cell responses
…, N Nguyen, W Chen, I Yurgelonis… - The Journal of …, 2022 - academic.oup.com
The development of a vaccine to prevent congenital human cytomegalovirus (HCMV) disease
is a public health priority. We tested rhesus CMV (RhCMV) prototypes of HCMV vaccine …
is a public health priority. We tested rhesus CMV (RhCMV) prototypes of HCMV vaccine …
[HTML][HTML] Neutralizing antibodies to human cytomegalovirus recombinant proteins reduce infection in an ex vivo model of developing human placentas
T Tabata, M Petitt, J Li, X Chi, W Chen, I Yurgelonis… - Vaccines, 2022 - mdpi.com
Human cytomegalovirus (HCMV) is the leading viral cause of congenital disease and
permanent birth defects worldwide. Although the development of an effective vaccine is a public …
permanent birth defects worldwide. Although the development of an effective vaccine is a public …
Non-propagating, recombinant vesicular stomatitis virus vectors encoding respiratory syncytial virus proteins generate potent humoral and cellular immunity against …
…, CS Kotash, RM Nowak, E Braunstein, I Yurgelonis… - Immunology …, 2013 - Elsevier
Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract illness in
infants, the elderly, and other high-risk individuals. Despite years of research in this field, …
infants, the elderly, and other high-risk individuals. Despite years of research in this field, …
Discovery of SARS-CoV-2 papain-like protease (PLpro) inhibitors with efficacy in a murine infection model
…, SK Sakata, TR Vargo, W Qi, H Wu, Y Liu, I Yurgelonis… - bioRxiv, 2024 - biorxiv.org
Vaccines and first-generation antiviral therapeutics have provided important protection
against coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome …
against coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome …
Discovery of orally active SARS-CoV-2 papain-like protease (PLpro) inhibitors (preprint)
…, SK Sakata, TR Vargo, W Qi, H Wu, Y Liu, I Yurgelonis… - 2024 - pesquisa.bvsalud.org
Vaccines and first-generation antiviral therapeutics have provided important protection
against coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome …
against coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome …
Nirmatrelvir, an orally active Mpro inhibitor, is a potent inhibitor of SARS-CoV-2 Variants of Concern (preprint)
DK Rai, I Yurgelonis, P McMonagle, HA Rothan, L Hao… - 2022 - pesquisa.bvsalud.org
New variants of SARS-CoV-2 with potential for enhanced transmission, replication, and
immune evasion capabilities continue to emerge causing reduced vaccine efficacy and/or …
immune evasion capabilities continue to emerge causing reduced vaccine efficacy and/or …